Existing Cancer Therapy in Narrow Use Shows Significant Activity against Other Cancers

A drug currently used in just 1% of cancers has significant potential against the remaining 99%, according to a new study from UH Seidman Cancer Center and Case Western Reserve University, published in the prestigious journal Nature Cancer. Ivosidenib, or AG-120, is currently used against cancers that have a mutation in the IDH1 gene. However, study results show that Ivosidenib is also effective against unmutated, or “wild-type” IDH1. The protein coded by the IDH1 gene in cancers helps cancer cells survive in a stressful tumor environment, so any inhibitor medication that could weaken this defense mechanism is considered a promising therapy. UH and CWRU scientists discovered that under conditions present in the tumor microenvironment, drugs previously believed to be selective for the mutant enzyme have activity against the normal protein. Specifically, low glucose and magnesium levels enhance drug activity. The team has now tested Ivosidenib in mouse models of pancreatic, colorectal, o

Roswell Park Researchers Identify Molecular ‘Glue’ That Sticks to and Degrades a Cancer-Causing Protein

A small molecule discovered and developed by a team of scientists led by Fengzhi Li, PhD, Associate Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center, eliminates human pancreatic and colorectal tumor cells by binding to and degrading DDX5, a powerful cancer-causing protein.

Henry Ford Health is First in the World to Offer Latest Advancement in MR-Guided Radiation Therapy

Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.

MD Anderson Research Highlights for June 1, 2022

Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.

Cedars-Sinai Cancer Experts Present Breakthroughs at 2022 ASCO Annual Meeting

Experts from Cedars-Sinai Cancer, ranked among the top 10 in the nation for cancer care, will present novel research and clinical advances throughout the 2022 annual meeting of the American Society of Clinical Oncology (ASCO), taking place in person and virtually June 3-7 in Chicago.

Breaking the shield that protects pancreatic cancer from immunotherapy

Scar-like cells that make up a sizable portion of malignant pancreatic tumors and shield these cancers from immune attack are derived from mesothelial cells that line tissues and organs, a new study led by UT Southwestern researchers suggests. The findings, published in Cancer Cell, could offer a new strategy to fight pancreatic cancer, a deadly disease for which no truly effective treatments exist.

April Research Highlights

This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.

AI May Detect Earliest Signs of Pancreatic Cancer

An artificial intelligence (AI) tool developed by Cedars-Sinai investigators accurately predicted who would develop pancreatic cancer based on what their CT scan images looked like years prior to being diagnosed with the disease. The findings, which may help prevent death through early detection of one of the most challenging cancers to treat, are published in the journal Cancer Biomarkers.

Pancreatic Cysts, Cancer and Awareness: Answers from an Expert

Russell Langan, MD, surgical oncologist at Rutgers Cancer Institute of New Jersey, chief of Surgical Oncology and Hepatopancreatobiliary Surgery at Saint Barnabas Medical Center (SBMC) and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, shares more information on monitoring pancreatic cysts and pancreatic cancer.

New Clinical Advances in Gastroenterology Presented at the American College of Gastroenterology’s 86th Annual Scientific Meeting

Featured science includes increased incidence of pancreatic cancer among young women, quality of life improvements in IBD, colorectal cancer risk from weight loss surgery and medications, and more

MD Anderson Research Highlights for September 22, 2021

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.

MD Anderson Research Highlights for August 11, 2021

Current advances include insights into anti-tumor responses, a targeted therapy combination for biliary tract cancers, biomarkers that may predict response to DNA damage repair inhibitors, a “virtual biopsy” using artificial intelligence to characterize tumors, new targeted and immunotherapy approaches for pancreatic cancer, understanding the impact of TP53 mutations on acute myeloid leukemia treatments, as well as a new strategy to overcome treatment-resistant KRAS-mutant lung cancer.

MD Anderson Research Highlights for June 30, 2021

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include expanded use of a targeted therapy for a new group of patients with leukemia, molecular studies yielding novel cancer therapeutic targets, insights into radiation therapy resistance and a community intervention to reduce cervical cancer rates.

Turning a pancreatic cancer cell’s addiction into a death sentence

Probing the unique biology of human pancreatic cancer cells in a laboratory has yielded unexpected insights of a weakness that can be used against the cells to kill them.

Led by Princess Margaret Cancer Centre Scientist Dr. Marianne Koritzinsky, researchers showed that about half of patient-derived pancreatic cancer cell lines are highly dependent or “addicted” to the protein peroxiredoxin 4 (PRDX4), as a result of the altered metabolic state of the cancer cell. This addiction, which is vital for the cancer cell’s survival, makes it a precise, potential target against the cancer.

Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting

Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.

MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.

New Biomarker May Predict Which Pancreatic Cancer Patients Respond to CD40 Immunotherapy

Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won’t respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight.

Henry Ford Health System Receives $16 Million Gift to Benefit Henry Ford Pancreatic Cancer Center

Henry Ford Health System today announced a $16 million gift to its Henry Ford Pancreatic Cancer Center (HFPCC), which was launched in 2018 by an initial $20 million gift from the same donor, who wishes to remain anonymous. The gift will bolster the HFPCC’s clinical and translational research endeavors in the fight against this devastating disease, for which the five-year survival rate is only 9 percent.

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.

Expert alert: Changing the outlook for pancreatic cancer

Pancreatic cancer often is hidden and doesn’t cause symptoms until it has spread. It is a leading cause of cancer deaths in the world.

November 19 is World Pancreatic Cancer Day, but the entire month of November is meant to bring awareness to this disease.

Advances in screening and early detection for high-risk people, minimally invasive surgical innovations and new genetic classifications are changing the outlook for pancreatic cancer, says Dr. Michael Wallace, a Mayo Clinic gastroenterologist.

Moderate-pace Walking Shrunk Pancreatic Cancer Tumors and Increased Cancer-killing Cells, Small Study Shows

Emily LaVoy, PhD, of the University of Houston, and colleagues explored the effects of moderate-intensity exercise on a mouse model of pancreatic cancer. Pancreatic cancer can be a particularly dangerous form of cancer because it is often diagnosed in later stages and spreads quickly. Though the trial sample was small—thus warranting further study—the results were optimistic.

New experimental blood test determines which pancreatic cancers will respond to treatment

GRAND RAPIDS, Mich. (Oct. 22, 2020) — Scientists have developed a simple, experimental blood test that distinguishes pancreatic cancers that respond to treatment from those that do not. This critical distinction could one day guide therapeutic decisions and spare patients with resistant cancers from undergoing unnecessary treatments with challenging side effects.

Deirdre J. Cohen, MD, MS, Appointed as Director of Gastrointestinal Oncology Program of Mount Sinai Health System

Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader has joined Mount Sinai Health System as Director of the Gastrointestinal (GI) Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.